CARA THERAPEUTICS INC
COM · CUSIP 140755109
* Summed across managers. Shares that two managers' reports both contain – a subsidiary's holdings that its parent's report includes too, or a sub-adviser's in its client's – are counted once. Holder counts are more reliable. Implied quarter-end price ≈ $0.35.
Trends to Q4 2024
Institutional holders
Managers reporting a position, each quarter
Numbers
| Quarter | Holders |
|---|---|
| Q3 2022 | 165 |
| Q4 2022 | 162 |
| Q1 2023 | 163 |
| Q2 2023 | 137 |
| Q3 2023 | 123 |
| Q4 2023 | 112 |
| Q1 2024 | 102 |
| Q2 2024 | 82 |
| Q3 2024 | 70 |
| Q4 2024 | 1 |
Buyers vs sellers
Managers adding to or starting a position, vs cutting or selling out
Numbers
| Quarter | Bought or added | Cut or sold out |
|---|---|---|
| Q1 2023 | 71 | 85 |
| Q2 2023 | 69 | 84 |
| Q3 2023 | 52 | 71 |
| Q4 2023 | 46 | 61 |
| Q1 2024 | 35 | 57 |
| Q2 2024 | 30 | 62 |
| Q3 2024 | 11 | 50 |
| Q4 2024 | 0 | 68 |
Calls vs puts
Options held, notional value, last 4 quarters. P/C = puts ÷ calls
Numbers
| Quarter | Calls | Puts | P/C |
|---|---|---|---|
| Q1 2024 | $45.5k | $3.5k | 0.08 |
| Q2 2024 | $15.5k | $129 | 0.01 |
| Q3 2024 | $1.6k | $0 | 0.00 |
| Q4 2024 | $0 | $0 | — |
Biggest buyers
| None |
Biggest sellers
| VANGUARD GROUP INC | Sold out | -2.2m |
| Chescapmanager LLC | Sold out | -1.7m |
| FARALLON CAPITAL MANAGEMENT, L.L.C. | Sold out | -1.6m |
| DISCIPLINED GROWTH INVESTORS INC /MN | Sold out | -1.1m |
| RENAISSANCE TECHNOLOGIES LLC | Sold out | -1.1m |
| TWO SIGMA ADVISERS, LP | Sold out | -866.3k |
| BlackRock, Inc. | Sold out | -742.5k |
| MILLENNIUM MANAGEMENT LLC | Sold out | -587.9k |
| BNP PARIBAS FINANCIAL MARKETS | Sold out | -582.5k |
| GEODE CAPITAL MANAGEMENT, LLC | Sold out | -452.2k |
Major shareholders (over 5%)
Anyone who owns more than 5% of a class of the company's shares has to say so: on Schedule 13D if they may try to influence or control the company, on 13G if they're a passive investor, and update it as the stake changes. Each holder's latest filing, from 19 Dec 2024 on; percentages are of the share class, as the holder worked them out.
| Holder | Stake |
|---|---|
Vifor (International) Ltd
13D · may seek influence
filed 2024-12-18
Stated purposeThe information set forth in Item 4 is hereby amended and supplemented to read as follows: Asset Purchase Agreement On December 17, 2024, the Issuer and its subsidiary Cara Royalty Sub, LLC ("Royalty Sub" and together with the Issuer, each, a "Seller" and together, the "Sellers") entered into an Asset Purchase Agreement (the "APA") with Vifor Fresenius Medical Care Renal Pharma, Ltd., a majority-owned, indirect subsidiary of CSL Limited ("CSL Vifor"), pursuant to which, at the consummation of the transaction, Sellers will sell to CSL Vifor and CSL Vifor will acquire from Sellers certain assets and rights for the development, manufacture and commercialization of difelikefalin as well as certain associated liabilities (the "Asset Disposition") for a purchase price of $900,000 (subject to … Full filing |
13.5% |
Holders, Q4 2024
| Manager | Shares | Change |
|---|---|---|
| Rathbones Group PLC 0.00% of their portfolio | 20.2k $7.2k | Unchanged |